title: Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck.
abstract: OBJECTIVE
  Twenty-seven patients with recurrent squamous cell carcinoma of the head and neck were entered in a multicenter study to determine the efficacy of the paclitaxel-carboplatin association.
  
  
  METHODS
  Standard eligibility criteria applied, i.e. measurable disease, and chemotherapy given as induction treatment or concomitant chemoradiotherapy was allowed if completed more than 6 months prior to the study. Every 21 days, paclitaxel 175 mg/m(2) and carboplatin AUC 6 were administered. The patient group included 3 females and 24 males with a median age of 61 years (range 39-75 years).
  
  
  RESULTS
  All patients were assessable for toxicity and 24 for responses. Main grade 3-4 toxicities were: neutropenia (62.9%), febrile neutropenia (18.5%), anemia (11.1%), thrombocytopenia (14.8%), mucositis (7.4%) and vomiting (7.4%). Among the intent-to-treat population, 29.6% of patients had an objective response, with a median response duration of 4.2 months (range 1-5.7 months). Stable and progressive disease were observed in 11.1 and 48.1% of patients, respectively. The median overall survival was 7.2 months (range 0.5-10.9 months).
  
  
  CONCLUSIONS
  From these data, paclitaxel-carboplatin seems to have an activity in recurrent squamous cell carcinoma of the head and neck, but the high level of toxicity highlights the need to search for a safer chemotherapy combination.
authors.affiliation: Centre Antoine Lacassagne, Nice, France. xavier.pivot@cal.nice.fnclcc.fr
authors.forename: X
authors.initials: X
authors.lastname: Pivot
authors.forename: L
authors.initials: L
authors.lastname: Cals
authors.forename: D
authors.initials: D
authors.lastname: Cupissol
authors.forename: E
authors.initials: E
authors.lastname: Guardiola
authors.forename: X
authors.initials: X
authors.lastname: Tchiknavorian
authors.forename: P
authors.initials: P
authors.lastname: Guerrier
authors.forename: L
authors.initials: L
authors.lastname: Merad
authors.forename: J L
authors.initials: JL
authors.lastname: Wendling
authors.forename: L
authors.initials: L
authors.lastname: Barnouin
authors.forename: J
authors.initials: J
authors.lastname: Savary
authors.forename: A
authors.initials: A
authors.lastname: Thyss
authors.forename: M
authors.initials: M
authors.lastname: Schneider
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel